Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Roche Pays $425 Million for GeneWEAVE, a Decheng Portfolio Company

publication date: Aug 13, 2015
Roche will acquire GeneWEAVE BioSciences, a Los Gatos, CA diagnostics company, for $425 million. Roche will pay $190 million up front and up to $235 million in milestones. GeneWEAVE’s Smarticles technology develops innovative molecular diagnostics that identify multidrug-resistant organisms (MDROs) along with their susceptibility to specific antibiotics, without requiring additional enrichment. Decheng Capital, a Shanghai healthcare investment firm, is the lead investor and largest shareholder in GeneWEAVE. More details....

Stock Symbol: (SIX: RO, ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital